AU Patent

AU2012339829B8 — Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Assigned to Novartis AG · Expires 2016-06-09 · 10y expired

What this patent protects

Patent listed against nilotinib-hydrochloride.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012339829B8
Jurisdiction
AU
Classification
—
Expires
2016-06-09
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.